Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation

M. özcan, C. Üstün, E. Akçağlayan, H. Akan, Arslan, O. Ilhan, M. Beksaç, G. Gürman, T. Demirer, M. Arat, H. Çelebi, N. Konuk, A. Uysal, H. Koç

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

We studied the effects of recombinant human granulocyte colony-stimulating factor (G-CSF) on hematopoietic recovery and clinical outcome in patients undergoing allogeneic peripheral blood stem cell (PBSC) transplantation. Fifty-six patients with hematological malignancies who underwent allogeneic PBSC transplantation between 1995 and 1998 were entered into this study. Twenty-eight patients who received daily G-CSF from day +1 after allogeneic PBSC transplantation until the absolute neutrophil count (ANC) reached >0.5 × 109/l for 3 consecutive days were compared with 28 patients (control group) who did not receive G-CSF in a non-randomized manner. The study group and the control group were comparable with respect to baseline patient and transplantation characteristics. Median times to ANC of >0.5 × 109/l and 1 × 109/l with or without G-CSF were 12 days (range 8-21), 13 days (10-32) (P=0.04) and 13 days (9-21), 15 days (11-44) (P=0.02), respectively. Median times to reach a platelet count of >20 × 109/l with and without G-CSF were 11 days (0-20) and 13 days (9-26), respectively (P=0.03). The incidence of febrile episodes was significantly lower with G-CSF, 75% vs 100% (P=0.008). Patients receiving G-CSF had less grade III-IV mucositis than those who did not receive G-CSF (P=0.01). There was also no increase in the incidence and severity of acute GVHD in patients using G-CSF (P=0.22). Although the number of relapsing patients was greater in the G-CSF group (seven vs three patients), this was not statistically significant (P=0.24). Disease-free and overall survival rates did not differ between the two groups (P=0.58 and 0.53, respectively). The administration of G-CSF after allogeneic PBSC transplantation provided faster neutrophil and platelet engraftment associated with less severe mucositis and less febrile episodes.

Original languageEnglish (US)
Pages (from-to)499-505
Number of pages7
JournalBone marrow transplantation
Volume27
Issue number5
DOIs
StatePublished - Jan 1 2001

Keywords

  • Allogeneic PBSC transplantation
  • G-CSF
  • GVHD

Fingerprint Dive into the research topics of 'Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation'. Together they form a unique fingerprint.

  • Cite this

    özcan, M., Üstün, C., Akçağlayan, E., Akan, H., Arslan, Ilhan, O., Beksaç, M., Gürman, G., Demirer, T., Arat, M., Çelebi, H., Konuk, N., Uysal, A., & Koç, H. (2001). Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Bone marrow transplantation, 27(5), 499-505. https://doi.org/10.1038/sj.bmt.1702816